Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine
Berik M Khairullin, PhD
Abstract
The study is a single centre, phase I, open, randomized, by intranasal and sublingual application trial that explored the safety and immunogenicity of 2 doses (Day 1 and Day 21) TB/FLU-01L tuberculosis vaccine in BCG-vaccinated healthy adult subjects aged 18-50 years.
MeSH terms
- Tuberculosis